The Dana-Farber Cancer Institute, a leader in advanced cancer research, announced the launch of the Center for RAS Therapeutics in their continued effort to improve the lives of atypical cancer patients around the world. This initiative will focus on research, treatments and clinical care for patients living with RAS-driven cancers.
The RAS mutation is found in approximately 20% of all the cancers world-wide, equating to 3.4 million cases. 92% of pancreatic cancers reported contain a RAS mutation, 54% of colorectal cancers.
The Center for RAS Therapeutics will be directed by 2 esteemed Dana-Farber physicians, Alice Shaw, MD, PhD and Andrew Aguirre, MD, PhD. Dr. Shaw will be the chief of strategic partnerships at the institution and is a thoracic oncologist with years of experience developing RAS inhibitors. Dr. Aguirre is a gastrointestinal oncologist and leading researcher at Dana-Farber and the Broad Institute of Harvard and MIT lab focusing on the RAS mutation in certain cancers.
Drs. Shaw and Aguirre will be concentrating the center’s efforts on developing RAS inhibitors and improving treatments for inhibitor resistant mutations.
For more information about the Dana-Farber Center for RAS Therapeutics, please click here.
Editor’s Note: Get Involved
Cancer doesn’t discriminate. WHATNEXT and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a cancer journey to share, reach out here to learn more about how your voice can help spread awareness and inspire individuals from all walks of life.
cancer cancer research colorectal cancer lung cancer oncology pancreatic cancer
Last modified: January 15, 2025
